The condition of aortitis due to pegfilgrastim is not rare and is approximated at 0.3%–0.7% among the cancer patients undergoing pegfilgrastim (G-CSF).6,7 Almost all the reported cases happened during the past decade and can probably be explained by increasing awareness and greater usage of long-acting forms of G-CSF.8 The analysis of 72 cases revealed a mean age of the patient to be around 62 years old with 80% of the cases falling among women—most of them being breast cancer or gynaecological malignancies.9 This evidence concerns the gene CSF3 and breast carcinoma.